Literature DB >> 12521798

Trial of scar or elective repeat caesarean section at maternal request?

L M Irvine1, R W Shaw.   

Abstract

In a study between 1 January 1996 and 31 December 1998 at Watford General Hospital, we identified all women who booked having had a previous caesarean section. Data on age, social class and previous obstetric history was extracted from the notes, as was mode of delivery. Of the 718 patients identified, 497 were considered suitable for trial of scar. Of these 221 (44.5%) requested repeat caesarean section. Age, social class and indication for previous caesarean section could not predict those who accepted trial of scar. Of the 60 women who had had a previous successful trial of scar 59 (98.3%) underwent trial of scar and of the 48 who had had a vaginal delivery prior to caesarean section 37 (77.1%) underwent trial of scar (P < 0.01). Maternal request for caesarean section, without obstetric contraindication to trial of scar, accounted for 24.9% of all the elective caesarean sections undertaken in our unit.

Entities:  

Year:  2001        PMID: 12521798     DOI: 10.1080/01443610120071992

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  3 in total

1.  Impact of a cultural belief about ghost month on delivery mode in Taiwan.

Authors:  Herng-Ching Lin; Sudha Xirasagar; Yu-Chi Tung
Journal:  J Epidemiol Community Health       Date:  2006-06       Impact factor: 3.710

2.  Cesarean and VBAC rates among immigrant vs. native-born women: a retrospective observational study from Taiwan Cesarean delivery and VBAC among immigrant women in Taiwan.

Authors:  Jung-Chung Fu; Sudha Xirasagar; Jihong Liu; Janice C Probst
Journal:  BMC Public Health       Date:  2010-09-10       Impact factor: 3.295

3.  Caesarean section rate and postnatal bed occupancy: a retrospective study replacing assumptions with evidence.

Authors:  Subhadeep Roy; L Montgomery Irvine
Journal:  BMC Health Serv Res       Date:  2018-10-05       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.